Clinical Trial Update: Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome [Phase 3]

View source ↗

Summary

This clinical trial update reports on the efficacy and safety of arbaclofen (STX209) for treating social withdrawal in children with Fragile X syndrome in a Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• STX209 (arbaclofen)

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 3 | Status: COMPLETED